BDX | Becton, Dickinson and Company

IndexS&P 500 P/E46.23 EPS (ttm)5.44 Insider Own0.10% Shs Outstand284.29M Perf Week-0.12%
Market Cap70.38B Forward P/E18.44 EPS next Y13.64 Insider Trans-0.51% Shs Float282.10M Perf Month0.18%
Income1.56B PEG4.69 EPS next Q2.90 Inst Own90.90% Short Float / Ratio0.91% / 2.28 Perf Quarter9.49%
Sales18.81B P/S3.74 EPS this Y3.70% Inst Trans-1.96% Short Interest2.56M Perf Half Y2.04%
Book/sh90.36 P/B2.78 EPS next Y11.76% ROA2.90% Target Price286.15 Perf Year-1.31%
Cash/sh7.10 P/C35.42 EPS next 5Y9.85% ROE6.00% 52W Range215.90 - 269.06 Perf YTD-1.10%
Dividend3.64 P/FCF541.42 EPS past 5Y3.10% ROI5.20% 52W High-6.53% Beta0.56
Dividend %1.45% Quick Ratio0.80 Sales past 5Y9.30% Gross Margin45.30% 52W Low16.49% ATR4.16
Employees77000 Current Ratio1.30 Sales Q/Q1.50% Oper. Margin11.80% RSI (14)52.44 Volatility1.70% 1.49%
OptionableYes Debt/Eq0.71 EPS Q/Q20.00% Profit Margin8.10% Rel Volume1.17 Prev Close249.50
ShortableYes LT Debt/Eq0.62 EarningsMay 04 BMO Payout66.30% Avg Volume1.12M Price251.50
Recom2.10 SMA201.17% SMA50-0.46% SMA2002.85% Volume1,318,327 Change0.80%
Date Action Analyst Rating Change Price Target Change
May-30-23Resumed Morgan Stanley Overweight $295
May-05-23Upgrade Piper Sandler Neutral → Overweight $260 → $290
Apr-12-23Upgrade KeyBanc Capital Markets Sector Weight → Overweight $304
Jan-03-23Upgrade BofA Securities Neutral → Buy $250 → $290
Dec-12-22Upgrade Citigroup Sell → Neutral $221 → $250
Jul-11-22Downgrade Citigroup Neutral → Sell $265 → $235
Jun-24-22Upgrade Wells Fargo Equal Weight → Overweight $275
Mar-18-22Resumed Raymond James Mkt Perform
Mar-02-22Resumed BofA Securities Neutral $290
Dec-08-21Downgrade Piper Sandler Overweight → Neutral $285 → $260
Jun-04-23 09:00AM
Jun-02-23 11:55AM
May-29-23 07:00AM
May-25-23 07:00AM
May-24-23 09:33AM
06:50AM Loading…
May-23-23 06:50AM
May-22-23 11:00AM
May-21-23 07:00AM
May-18-23 11:15AM
May-16-23 07:00AM
May-12-23 09:53AM
May-08-23 12:52PM
May-04-23 03:21PM
11:20AM Loading…
May-03-23 02:08PM
Apr-26-23 04:15PM
Apr-25-23 04:15PM
Apr-22-23 09:00AM
12:11PM Loading…
Apr-21-23 12:11PM
Apr-19-23 06:50AM
Apr-17-23 08:22AM
Apr-14-23 11:40AM
Apr-12-23 11:57AM
Apr-11-23 08:00AM
Apr-07-23 09:40AM
Apr-06-23 04:15PM
Apr-03-23 04:10PM
Mar-29-23 11:40AM
Mar-28-23 02:29PM
Mar-27-23 07:27AM
Mar-23-23 02:56PM
Mar-17-23 10:40AM
Mar-16-23 08:00AM
Mar-15-23 10:57AM
Mar-14-23 01:09PM
Mar-11-23 09:00AM
Mar-10-23 03:56PM
Mar-08-23 12:05PM
Mar-07-23 10:15AM
Mar-06-23 11:40AM
Mar-04-23 07:16AM
Mar-03-23 07:22AM
Mar-02-23 12:01PM
Mar-01-23 04:15PM
Feb-28-23 07:00AM
Feb-27-23 10:49AM
Feb-22-23 05:54PM
Feb-21-23 04:15PM
Feb-19-23 10:11AM
Feb-17-23 04:24PM
Feb-15-23 11:53AM
Feb-14-23 06:54PM
Feb-10-23 12:41PM
Feb-08-23 06:50AM
Feb-07-23 11:40AM
Feb-06-23 02:07AM
Feb-03-23 06:50AM
Feb-02-23 02:28PM
Feb-01-23 09:07AM
Jan-31-23 08:07AM
Jan-30-23 10:22AM
Jan-27-23 08:52AM
Jan-26-23 10:01AM
Jan-25-23 06:50AM
Jan-24-23 04:15PM
Jan-23-23 10:05AM
Jan-17-23 09:17AM
Jan-11-23 08:00AM
Jan-09-23 06:50AM
Jan-06-23 04:15PM
Jan-05-23 04:15PM
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Byrd RichardEVP & President InterventionalFeb 03Sale248.601,421353,2614,119Feb 06 04:06 PM
Goette RolandEVP and President, EMEANov 16Option Exercise74.944,617345,99814,896Nov 18 08:41 AM
Polen Thomas E JrChairman, CEO and PresidentAug 15Option Exercise167.9115,0002,518,65043,878Aug 17 07:19 AM
Polen Thomas E JrChairman, CEO and PresidentAug 15Sale265.139,5002,518,73528,878Aug 17 07:19 AM
Hickey DavidEVP & President, Life SciencesAug 15Sale265.00475125,8753,331Aug 17 07:21 AM
Khichi Samrat S.EVP and General CounselAug 09Option Exercise100.3626,8152,691,27220,254Aug 11 04:24 PM
Polen Thomas E JrExecutive Vice PresidentAug 09Option Exercise147.683,825564,87632,703Aug 11 04:23 PM
Khichi Samrat S.EVP and General CounselAug 09Sale260.449,1852,392,1415,928Aug 11 04:24 PM
Polen Thomas E JrExecutive Vice PresidentAug 09Sale260.001,652429,52028,878Aug 11 04:23 PM
Khichi Samrat S.EVP and General CounselAug 08Sale260.447,2951,899,9105,928Aug 11 04:24 PM